!

COVID-19 Response

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Baylor College of Medicine

Investigational Medication for OCD (H-42023)

Description

Content

BVH4157-202: A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder

Are you between the ages of 18 and 65, diagnosed with obsessive compulsive disorder (OCD), and are not satisfied with your current SSRI medication?

Baylor College of Medicine Menninger Department of Psychiatry and Behavioral Sciences is conducting a clinical trial of an investigational medication for OCD, compared to a placebo. The medication would be added onto your current treatment, and your involvement in the study would include 7 visits to our clinic over 12 weeks (possibly more after that if you would like to continue taking the medication). You will be compensated for your time and participation.

If you are interested, would like more information, or would like to see if you qualify, please contact the study coordinator at (713) 798-4729 or email gsvogt@bcm.edu.

More information

Contact

Gregory Vogt

Phone 1: 713–798–4729

IRB: H-42023

Status:

Active

Created:

Back to topback-to-top